Cannabis Science Negotiates for a 7,500 Sq. Ft., Facility in Colorado Springs to Facilitate Both Research and Revenues in the Company's Five Divisions

COLORADO SPRINGS, Colo. - Cannabis Science, Inc. (OTCBB:CBIS - News), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce it is in negotiations for a 7,500 square foot facility in Colorado Springs, CO that will allow the company to develop both research and revenues in compliance with state laws and federal guidelines.

With the rapid expansion occurring in the Company's five divisions: Horticulture, Analytical Labs, Manufacturing, Clinical Trials and Distribution, Cannabis Science is negotiating for a space that will allow continued growth for all of its current and future business operations. The past few months have proven to be very successful for the Company, with many new revenue opportunities developing as a result of its overwhelming interest from media, patients, partners and shareholders. Announcements of the recent Company developments are scheduled for the next few days. Cannabis Science is very pleased to be experiencing steady expansion in its five divisions.

1. Horticulture Division -- Pharmaceutical Grade Medical Cannabis Grown Under Stringent Quality Controls.

2. Analytical Labs -- State Of The Art Facilities For Developing Cannabis Based Extracts and Pharmaceutical Grade Drugs.

3. Manufacturing -- Cutting Edge Facilities For Creating Oral and Topical Medications For Various Ailments.

4. Clinical Trials -- Initial Clinical Trials for FDA Approval Will Target Veterans Suffering From Chronic Pain and PTSD.

5. Distribution -- In State Dispensaries Today, National Pharmacies Tomorrow.

Richard Cowan, Cannabis Science CFO, concluded, "We are very pleased with the enormous media interest and the support we have received over the last few months from our increasing list of partners, patients & shareholders. Steady expansion in the Company has provided us with the exciting opportunity to negotiate for a new space in Colorado Springs, CO that will accommodate the upcoming operational expansions in the Company. The Company will be making very exciting announcements over the next few days outlining these new business expansions and relationships."

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.